Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 11/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | FABP3 | P05413 | 1/20 | 0.40 |
| ▸ | PIN1 | Q13526 | 2/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1843692 | 0.90 | SIRT1 (0.53) | SIRT1FABP4PTGDR2 | |
| SCHEMBL13930553 | 0.86 | SRD5A1 (0.46) | SIRT1FABP4DRD2DRD1PIN1 | |
| SCHEMBL14915975 | 0.85 | SIRT1 (0.47) | SIRT1DRD2DRD1PIN1TRPV1 | |
| SCHEMBL30799420 | 0.84 | PIN1 (0.48) | PIN1 | |
| SCHEMBL28295382 | 0.82 | DRD2 (0.38) | SIRT1DRD2DRD1PIN1TRPV1 | |
| SCHEMBL14310636 | 0.82 | ANO1 (0.40) | DRD2DRD1PIN1PTGDR2TRPV1 | |
| SCHEMBL10469026 | 0.79 | FABP4 (0.43) | FABP4FABP3PTGDR2 | |
| SCHEMBL2789968 | 0.79 | PIN1 (0.50) | FABP4FABP3PIN1 | |
| SCHEMBL29609152 | 0.79 | PIN1 (0.50) | FABP4FABP3PIN1 | |
| SCHEMBL8796023 | 0.79 | FABP4 (0.43) | FABP4DRD1FABP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | claimed |
| EP-1748984-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | Pfizer Products Inc. (US) | 2007-02-07 | — | — | EP | disclosed |
| WO-2005110987-A1 | PIPERIDINE DERIVATIVES AS NK1 AND NK3 ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| US-20050256164-A1 | NK1 and NK3 antagonists | PFIZER INC | 2005-11-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050256164-A1 | NK1 and NK3 antagonists | TAC3, TACR1, TACR2 | SIRT1 4210/4885FABP4 3579/4885DRD2 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.